May 18th 2024
A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
2 Surveys Highlight Rheumatologists' Knowledge Gaps With Biosimilars
November 6th 2017Two posters presented today at the American College of Rheumatology’s 2017 meeting in San Diego, California, highlight the gaps in US rheumatologists’ knowledge concerning biosimilar therapies, and underscore the importance of greater physician education about biosimilar medicines.
New Data Support Switching to Biosimilar CT-P13 in Patients With Crohn's Disease
October 30th 2017New data show that switching patients with Crohn’s disease to CT-P13 from the reference infliximab led to comparable efficacy, safety, and tolerability between the 2 treatments over a 24-week period. The full 54-week results of the phase 3 study support the long-term effectiveness of treatment with CT-P13, the researchers say.
Risankizumab Outperforms Humira, Stelara in Treating Plaque Psoriasis
October 27th 2017As AbbVie’s best-selling Humira faces oncoming biosimilar competition, the drug maker is developing a new innovator product that could help it retain a hold on the market; new results from 3 phase 3 clinical trials show AbbVie’s investigational interleukin-23 inhibitor, risankizumab, to be more effective than adalimumab (Humira) or ustekinumab (Stelara) in patients with moderate-to-severe plaque psoriasis.
Consensus Recommendations on Pegfilgrastim for Prophylaxis of Febrile Neutropenia
October 23rd 2017A paper by Matti Aapro, MD, recently published in Supportive Cancer Care, outlined, for the first time, consensus recommendations on using pegfilgrastim in particular patients and therapeutic scenarios.
Long-Term Data Support Switching From Reference Infliximab to SB2
October 21st 2017New data from an extension period of a phase 3 study of Samsung Bioepis’ SB2 (Renflexis) in patients with moderate to severe rheumatoid arthritis found that there was no clinically meaningful difference in safety, efficacy, or immunogenicity in patients who were switched from reference infliximab to the biosimilar compared with patients who continued treatment with either the reference or the biosimilar without switching.
Study Reports 24% Discontinuation Rate After Switching From Remicade to Biosimilar CT-P13
October 19th 2017A Dutch study reports that 24% of patients who switched from originator infliximab to CT-P13, an infliximab biosimilar, discontinued the biosimilar by their 6-month follow-up, mainly for reasons researchers termed “subjective” health complaints.
Report: Orphan Drugs Represent a Small Share of US Prescription Drug Spending
October 19th 2017While no one argues that orphan drugs that treat rare diseases can be expensive, the drugs’ reputation for being budget-busters is not borne out by a data presented in a recent report by Quintiles IMS Institute.
Biosimilars and the Nocebo Effect
October 18th 2017Switching patients from originator biologics to biosimilars is associated with the potential for a “nocebo” effect, a phenomenon that occurs when a patient’s negative expectation causes a treatment to have a more negative effect than it otherwise would—essentially, the opposite of the placebo effect.